- Title:
Appointment of Director & Grant of Options - Time:
07:00:05 - Date:
29 Jun 2021 - Category:
Director/PDMR dealings - ID:
3962D
29 June 2021
Kanabo Group Plc
("Kanabo" or "the Company")
Kanabo appoints Dr Daniel Poulter MP as Non-Executive Director
Kanabo Group Plc (LSE:KNB) is pleased to announce that it has appointed Dr Dan Poulter MP as a Non-Executive Director to the board. As both a former UK Government health minister, and as the chairperson of the All-Party Parliamentary Group for Global Health, Dr Poulter has a detailed knowledge of the drugs and medicines regulatory framework in the UK. His blend of medical, governmental, and healthcare policy experience makes him well positioned to support Kanabo's mission to establish and lead a regulated medicinal cannabis market in the UK and Europe.
Dr Poulter is a practicing NHS Psychiatrist who believes that prescribed cannabis products could bring considerable health benefits to help people experiencing mental ill health and distress. He has previously been involved in advocating medical cannabis for the benefit of patients through his work on a number of medical and policy bodies.
There is no further information required to be disclosed pursuant to Listing Rule 9.6.13 (1) - (6) of the Financial Conduct Authority in respect of Dr Poulter.
As part of his appointment, the Company has granted Dr Poulter options over 1,800,000 Ordinary Shares at an exercise price per option of 19.7p.
Avihu Tamir, CEO, Kanabo Group, said,
"We are delighted to welcome Dr Dan Poulter, MP as a Non-Executive Director to our board. Dan brings a wealth of knowledge and insight into the business that strengthens our team as we build a medicinal cannabis market in the UK and Europe."
Dr Daniel Poulter MP, said,
"As a doctor, I am increasingly aware of the potential of cannabis-based medicines. Cannabis products are fast becoming available that could deliver significant improvements to the lives of thousands of patients suffering from conditions ranging from chronic pain to post traumatic stress disorder.
Kanabo is an established leader in medical cannabis research and innovation. As such the company is creating a new standard in the industry by providing better and safer access to such cannabis medications. I am pleased to be able to lend my knowledge and experience to the company's work in this crucially important endeavour."
Chairman of the Board, David Tsur added,
"We are delighted that Dr Dan Poulter has joined us and we'd like to warmly welcome him. He brings a wealth of experience and I'm sure will be a very valuable addition to the Board. It's an exciting period for Kanabo to execute the company's business plan and to expand its activity and strategic partnerships."
-ENDS-
For further information, please visit http://www.kanabogroup.com/ or contact the following:
Kanabo Group Plc
Tel: +(972)52-3173-633
Meirav Horn
Peterhouse Capital Limited (Financial Adviser)
Tel: +44 (0)20 7469 0930
Eran Zucker / Guy Miller / Allie Feuerlein
Peterhouse Capital Limited (Corporate Broker)
Lucy Williams / Charles Goodfellow
| Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. |
||
| 1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
| a) |
Name |
Daniel Poulter |
| 2 |
Reason for the notification |
|
| a) |
Position/status |
Non-Executive Director |
| b) |
Initial notification /Amendment |
Initial Notification |
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
| a) |
Name |
Kanabo Group Plc |
| b) |
LEI |
213800XPJFSNWJIYKN52 |
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
| a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 2.5 pence each in Kanabo Group Plc
GB00BYQCS703 |
| b) |
Nature of the transaction |
Grant of options as part of the employee share option programme |
| c) |
Price(s) and volume(s) |
19.7 pence for each of 1,800,000 options |
| d) |
Aggregated information - Aggregated volume - Price |
1,800,000 options
£0.197 per share
|
| e) |
Date of the transaction |
On or around 29 June 2021 |
| f) |
Place of the transaction |
Standard List of the Main Market |
ABOUT KANABO GROUP PLC:
Kanabo aims to be an industry leader in product development and commercialisation of both cannabis-derived products for medical patients and THC-free products for CBD consumers. It develops high-quality medical cannabis extract formulas, medical device vaporisers, and other innovative delivery methods. Validation activities are conducted at Kanabo's research lab at the Weizmann Science Park in Israel. With a primary focus on the German and UK Markets, Kanabo has already begun penetrating the European Market, and is positioned to scale up to meet growing market demand and projected sales. Currently, Kanabo is selling its line of CBD formulas for inhalation in the UK and Germany and has agreements with distributors in the pharmaceutical and OTC sectors already in place.
Appointment of Director & Grant of Options07:00:0529 Jun 2021Director/PDMR dealings3962D